Compare Moderna, Inc. (MRNA) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Moderna, Inc. trades at $137 (market cap $56.02B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.39. The key difference: Moderna, Inc. is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MRNA | XDTE | |
|---|---|---|
Market Cap | $56.02B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $174.38 | $44.76 |
52-Week Low | $22.36 | $36.00 |
Enterprise Value | $52.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
XDTE trades at $38.60, down 0.5% on the day, with technical indicators showing bearish momentum as moving averages signal selling pressure. The ETF's weekly dividend strategy has generated significant attention, with recent payouts ranging from $0.09 to $0.26 per share. However, financial ratios remain unavailable, limiting fundamental analysis. Recent news coverage highlights concerns about the sustainability of XDTE's high yield strategy and fee structure compared to alternatives.
The outlook for XDTE appears cautious due to questions about dividend sustainability and competitive fee pressures. While the weekly income strategy attracts yield-seeking investors, structural risks and bearish technical signals suggest limited near-term upside potential. Investors should weigh the high distribution yield against potential total return underperformance in rising markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
